IVI seeks comment on its new NSCLC model through April 1, 2019.
This article was authored by Mark Linthicum, MPP, director of scientific communications at Innovation and Value Initiative
The adoption of value-based payments continues to grow, albeit slowly. About half of 150 healthcare executives who responded to a recent survey said that between half and three-quarters of their current contracts are in value-based models. This confirms other data that show US healthcare payments tied to value-based care increased in 2017 to 34%, an increase from 23% over 2 years.
Value-based healthcare is predicated on collaboration. Sharing of data, methods, pathways and perspectives among different stakeholders is paramount if the transition to value-based care is to be fully realized.
But does value mean the same thing to a patient and an insurer? A physician? An employer? Each of the stakeholders affected by value-based care has a unique perspective on what actually constitutes value. For value-based healthcare to succeed, all these perspectives must be honored and included.
Instead of relying solely on legacy methods to measure value, a process for all stakeholder perspectives to be heard and addressed is needed. But until now, there hasn’t been a transparent process for doing so, leaving decision makers who measure value from payer, employer, patient and manufacturer perspectives relegated to their separate camps.
That’s why the Innovation and Value Initiative launched the Open-Source Value Platform (OSVP). The OSVP uses a transparent and open-source process to develop methods and tools to estimate the value of medical technologies in a way that is patient-centric, allows for a broad range of perspectives, incorporates the latest available evidence and considers the full range of scientifically defensible approaches.
The OSVP isn’t intended to be single framework for measuring value. Rather, it’s a platform and process to build trust and collaboration with the goal of finding common ground and improved approaches that unlock value for the ultimate consumer in healthcare: patients. We invite your participation.
Last month IVI launched its second disease-specific value assessment platform for measuring the relative value of sequential treatments for epidermal growth factor receptor positive non-squamous non-small cell lung cancer (NSCLC), which can be found on our website. IVI’s disease-specific models serve as a laboratory to test and improve approaches to value assessment, and as a forum for collaboration across all stakeholders. Models evolve over time, driven by the feedback we receive during open public comment periods from stakeholders like you.
The public comment period for our new NSCLC model will remain open until April 1, 2019, and IVI highly encourages and welcomes comments, suggestions and critiques. Please take the time to take a tour and examine the model and consider providing your comments.
We think the only avenue to realize value--in outcomes, costs, quality and patient experience--is through transparency, collaboration and iteration. We hope by commenting on the NSCLC model, you’ll join us taking an important step on the value journey.
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More